Enasidenib (Idhifa)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From the NCI Drug Dictionary: An orally available inhibitor of isocitrate dehydrogenase type 2 (IDH2), with potential antineoplastic activity. Upon administration, enasidenib specifically inhibits IDH2 in the mitochondria, which inhibits the formation of 2-hydroxyglutarate (2HG).[1]

Diseases for which it is used

History of changes in FDA indication

History of changes in Health Canada indication

  • 2019-02-06: Initial notice of compliance with conditions for the treatment of adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with an isocitrate dehydrogenase-2 IDH2 mutation.

Patient Drug Information

Also known as

  • Code names: AG-221, CC-90007
  • Generic name: enasidenib mesylate
  • Brand name: Idhifa